Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Rev. bras. reumatol ; 57(6): 590-595, Nov.-Dec. 2017. tab
Artigo em Inglês | LILACS | ID: biblio-899480

RESUMO

Abstract Anti-tumor necrosis factor drugs are frequently preferred in the treatment of rheumatologic diseases and other inflammatory diseases. The development of myositis after using anti-tumor necrosis factor drugs is a rare clinical condition. Here we aimed to report cases who developed myositis after using anti-tumor necrosis factor drugs and review the current literature. We report two cases of rheumatoid arthritis and a case of ankylosing spondylitis developed idiopathic inflammatory myopathy following anti-tumor necrosis factor therapy. In conclusion, myositis could develop during anti-tumor necrosis factor therapy, so these patients should be evaluated carefully initially for myositis and should be closely monitored due to the potential for developing myositis in treatment process.


Resumo Os fármacos antifator de necrose tumoral (anti-TNF) são frequentemente preferidos no tratamento de doenças reumatológicas e outras doenças inflamatórias. O desenvolvimento de miosite após o uso de anti-FNT é uma condição clínica rara. Este estudo objetivou descrever casos de pacientes que desenvolveram miosite após o uso de anti-TNF e fazer uma revisão da literatura atual. Descrevem-se dois casos de artrite reumatoide (AR) e um caso de espondilite anquilosante (EA) que desenvolveram miopatia inflamatória idiopática após o tratamento com anti-TNF. Em conclusão, pode haver desenvolvimento de miosite durante o tratamento com anti-TNF, de modo que esses pacientes devem ser cuidadosamente avaliados inicialmente à procura de miosite e devem ser cuidadosamente monitorados em razão do potencial de desenvolvimento de miosite no processo de tratamento


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Antirreumáticos/efeitos adversos , Adalimumab/efeitos adversos , Etanercepte/efeitos adversos , Miosite/induzido quimicamente , Artrite Reumatoide/tratamento farmacológico , Espondilite Anquilosante/tratamento farmacológico , Adalimumab/administração & dosagem , Etanercepte/administração & dosagem , Miosite/diagnóstico
2.
Rev Bras Reumatol Engl Ed ; 57(6): 590-595, 2017.
Artigo em Inglês, Português | MEDLINE | ID: mdl-29173693

RESUMO

Anti-tumor necrosis factor drugs are frequently preferred in the treatment of rheumatologic diseases and other inflammatory diseases. The development of myositis after using anti-tumor necrosis factor drugs is a rare clinical condition. Here we aimed to report cases who developed myositis after using anti-tumor necrosis factor drugs and review the current literature. We report two cases of rheumatoid arthritis and a case of ankylosing spondylitis developed idiopathic inflammatory myopathy following anti-tumor necrosis factor therapy. In conclusion, myositis could develop during anti-tumor necrosis factor therapy, so these patients should be evaluated carefully initially for myositis and should be closely monitored due to the potential for developing myositis in treatment process.


Assuntos
Adalimumab/efeitos adversos , Antirreumáticos/efeitos adversos , Etanercepte/efeitos adversos , Miosite/induzido quimicamente , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab/administração & dosagem , Adulto , Artrite Reumatoide/tratamento farmacológico , Etanercepte/administração & dosagem , Feminino , Humanos , Masculino , Miosite/diagnóstico , Espondilite Anquilosante/tratamento farmacológico , Adulto Jovem
3.
Rev Bras Reumatol ; 2016 Mar 06.
Artigo em Inglês, Português | MEDLINE | ID: mdl-27004932

RESUMO

Anti-tumor necrosis factor (anti-TNF) drugs are frequently preferred in the treatment of rheumatologic diseases and other inflammatory diseases. The development of myositis after using anti-TNF is a rare clinical condition. Here we aimed to report cases who developed myositis after using anti-TNF and review the current literature. We report two cases of rheumatoid arthritis (RA) and a case of ankylosing spondylitis (AS) developed idiopathic inflammatory myopathy following anti-TNF therapy. In conclusion, myositis could develop during anti-TNF therapy, so these patients should be evaluated carefully initially for myositis and should be closely monitored due to the potential for developing myositis in treatment process.

4.
Wien Klin Wochenschr ; 128(21-22): 816-821, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26142171

RESUMO

BACKGROUND: Fibromyalgia syndrome (FMS) is an extra-articular rheumatic illness, characterized by widespread body pain and decreased muscle function. Generalized loss of muscle mass and strength is named as sarcopenia. The objective of this study was to evaluate patients with FMS regarding sarcopenia. METHODS: This was a cross sectional, case-controlled, single-blinded, and single-centered study. The FMS patients were assessed by Fibromyalgia Impact Questionnaire (FIQ), visual analog scale (VAS), Beck Depression Index (BDI), and Pittsburg Sleep Quality Scale (PSQI). All the participants were evaluated for sarcopenia by bioimpedance analysis (BIA), anthropometric measurements, handgrip strength, and the parameters of walking speed. RESULTS: In this study, 82 patients with FMS and 38 healthy control female subjects were included. VAS, BDI, and PSQI scores were statistically higher in the FMS group than the control group (p < 0.001). Handgrip strength (HS) and walking speed (WS) scores in the group with FMS were statistically lower than the control group (p = 0.023, p < 0.001 respectively). VAS score of FMS patients was significantly correlated with BIA, body mass index, waist circumference, HS, and WS scores (r = 0.284, p = 0.012; r = 0.228, p = 0.045; r = 0.249, p = 0.028; r = - 0.361, p = 0.001; and r = - 0.230, p = 0.043 respectively). Also FIQ in patients was significantly correlated with BIA, waist circumference, HS, WS, and body mass index (r = 0.267, p = 0.018; r = 0.291, p = 0.010; r = - 0.319, p = 0.004; r = - 0.360, p = 0.001; and r = 0.304, p = 0.007 respectively). CONCLUSION: Evaluation of female patients with primary FMS by the sarcopenia parameters could contribute a more objective evaluation during the patients' follow-up.


Assuntos
Fibromialgia/diagnóstico , Medição da Dor/métodos , Exame Físico/métodos , Sarcopenia/diagnóstico , Avaliação de Sintomas/métodos , Adulto , Estudos de Casos e Controles , Estudos Transversais , Diagnóstico Diferencial , Feminino , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Método Simples-Cego , Saúde da Mulher
5.
J Rheumatol ; 42(11): 2106-9, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26472411

RESUMO

OBJECTIVE: Acne vulgaris is a chronic inflammatory disease involving the pilosebaceous unit of the skin. Isotretinoin is a systemic retinoid that is often used as an effective treatment option for severe and treatment-resistant acne. Isotretinoin may also cause rheumatologic symptoms. The aim of this prospective observational study was to present followup results regarding the rheumatologic symptoms of patients who received systemic therapy for the treatment of acne (isotretinoin and tetracycline). METHODS: For inclusion in the study, all consecutive patients with acne who were aged > 18 years were evaluated by the same dermatologist. The first 42 consecutive patients were included in the isotretinoin group, and after matching for age and sex, 32 consecutive patients were included in the tetracycline group. Isotretinoin treatment was planned as an average dose of 30 mg daily and a total dose of 120-150 mg/kg for 4-6 months. The patients were administered a dose of 1 g/day of tetracycline as 2 equal doses for 3 months. RESULTS: Forty-two patients diagnosed with acne vulgaris were treated with isotretinoin 20.6 ± 4.4 (male/female: 17/22), and 32 patients were treated with tetracycline 20.6 ± 2.7 (male/female: 8/24). There was no significant difference between the 2 groups with respect to age and sex. Unilateral Achilles enthesopathy developed in 3 patients, whereas both Achilles enthesopathy and unilateral sacroiliitis developed in 1 patient. Inflammatory back pain developed in 6 patients in the isotretinoin group. CONCLUSION: To our knowledge, this was the first prospective observational study that assessed the rheumatologic symptoms of isotretinoin treatment. The spondyloarthropathy findings were identified in 23.1% of the patients who used isotretinoin.


Assuntos
Acne Vulgar/tratamento farmacológico , Isotretinoína/efeitos adversos , Espondiloartropatias/induzido quimicamente , Tetraciclina/uso terapêutico , Acne Vulgar/diagnóstico , Adolescente , Distribuição por Idade , Estudos de Coortes , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Humanos , Incidência , Isotretinoína/uso terapêutico , Masculino , Estudos Prospectivos , Medição de Risco , Índice de Gravidade de Doença , Distribuição por Sexo , Espondiloartropatias/epidemiologia , Espondiloartropatias/fisiopatologia , Tetraciclina/efeitos adversos , Adulto Jovem
6.
Aging Clin Exp Res ; 27(5): 751-3, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25725635

RESUMO

Liraglutide is a glucagon-like peptide-1 analog and recently started to be using as an incretin-based treatment for diabetes mellitus. Liraglutide causes some adverse affects including nausea, vomiting, acute nasopharyngitis and acute pancreatitis. However, development of liraglutide-dependent cholelithiasis has not been reported in the literature. A 75-year-old female patient had been diagnosed with type 2 diabetes mellitus for 10 years and she has been treated by liraglutide for 6 months. The patient was admitted to the emergency service due to sudden onset of abdominal pain. After laboratory and imaging studies, she was diagnosed with acute cholecystitis and cholelithiasis. And then patient's oral intake was stopped, intravenous fluid and ceftriaxone 2 g/day were started. Furthermore, liraglutide treatment discontinued and ursodeoxycholic acid (UDCA) was started to treat cholelithiasis. During follow-up, abdominal pain completely relieved. Hepatobiliary ultrasonography in sixth month follow-up showed entirely regression of cholelithiasis. Any liraglutide-related cholelithiasis case has not been reported in the literature previously. Therefore, our case is the first case. Especially, elderly diabetic patients who are started to liraglutide treatment should be monitored closely for the formation of cholelithiasis. UDCA treatment would be an alternative prior to surgical treatment for liraglutide-related cholelithiasis.


Assuntos
Colelitíase , Diabetes Mellitus Tipo 2/tratamento farmacológico , Liraglutida , Idoso , Colagogos e Coleréticos/administração & dosagem , Colelitíase/induzido quimicamente , Colelitíase/diagnóstico , Colelitíase/fisiopatologia , Colelitíase/terapia , Feminino , Peptídeo 1 Semelhante ao Glucagon/análogos & derivados , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/efeitos adversos , Liraglutida/administração & dosagem , Liraglutida/efeitos adversos , Resultado do Tratamento , Ácido Ursodesoxicólico/administração & dosagem , Suspensão de Tratamento
7.
Clin Rheumatol ; 34(7): 1259-63, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24816545

RESUMO

Like many chronic illnesses, Behçet's disease (BD) has been reported to negatively affect the quality of life and mental health of the individuals diagnosed with this disease. This study aims to investigate the relationship between disease activity and depression and sleep quality in BD. Forty patients with BD and 30 healthy subjects (controls), aged 18-65, were included in this study, and all of the subjects enrolled in this study were assessed in terms of depression and sleep quality using the Beck depression index (BDI) and Pittsburg sleep quality index (PSQI). Additionally, the subjects with BD were also assessed using the Behçet's disease current activity form (BDCAF). It was determined that the depression and sleep quality scores were significantly higher in the BD group compared to those in the control group (p = 0.012 and p = 0.020, respectively), and in the BD group, significant positive correlations were determined between the BDCAF and depression and sleep quality scores (r = 0.559, p < 0.001 and r = 0.462, p = 0.003, respectively). We believe that the assessment of BD patients for depressive symptoms and sleep quality, and providing medical support to those who need it, will contribute to the treatment and follow-up processes of BD.


Assuntos
Síndrome de Behçet/complicações , Síndrome de Behçet/psicologia , Depressão/complicações , Transtornos do Sono-Vigília/complicações , Sono , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Índice de Gravidade de Doença , Inquéritos e Questionários , Adulto Jovem
8.
BMJ Case Rep ; 20142014 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-24827659

RESUMO

Bladder cancer most commonly spreads to the lymph nodes, lungs, bones and adrenal glands. Metastasis of bladder cancer to the skeletal muscle is extremely rare, as is the case in other malignancies. We report a case of a 62-year-old male patient who presented with pain and swelling in the right lower extremity and had difficulty walking, and who was later found to have metastasis in the adductor longus muscle 3 months after the initial diagnosis of transitional cell carcinoma of the urinary bladder. The study also provides a review of the current literature.


Assuntos
Carcinoma de Células de Transição/patologia , Neoplasias Musculares/secundário , Músculo Esquelético/patologia , Coxa da Perna/patologia , Neoplasias da Bexiga Urinária/patologia , Bexiga Urinária/patologia , Humanos , Masculino , Pessoa de Meia-Idade
9.
BMJ Case Rep ; 20142014 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-24711475

RESUMO

Stiff person syndrome (SPS) is a rare condition that causes rigidity in the muscles of the body and extremities, difficulty in walking, episodic spasms and progressive disability. SPS is generally seen together with autoimmune disorders such as diabetes mellitus, thyroiditis, vitiligo and pernicious anaemia. Rarely, it may develop as a paraneoplastic condition. SPS cases associated with breast cancer, small cell lung carcinoma, thymoma, Hodgkin's lymphoma and colorectal cancer have been reported in the literature. We present a case of a 58-year-old female patient who had malignant mesothelioma-associated SPS. Patients who have muscle spasms and difficulty in movement of joints should be evaluated for SPS before diagnosis of Parkinson's or other neurological disorders, and possible underlying malignancies should be excluded.


Assuntos
Neoplasias Pulmonares/diagnóstico , Mesotelioma/diagnóstico , Rigidez Muscular Espasmódica/diagnóstico , Feminino , Humanos , Neoplasias Pulmonares/complicações , Mesotelioma/complicações , Mesotelioma Maligno , Pessoa de Meia-Idade , Rigidez Muscular Espasmódica/etiologia
10.
Case Rep Nephrol ; 2013: 724693, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24527250

RESUMO

A 30-year-old woman has presented complaining of weakness and fatigue to her primary care physician. The renal sonography is a routine step in the evaluation of new onset renal failure. When the renal masses have been discovered by sonography in this setting, the functional imaging may be critical. We reported a case about bilateral renal masses in a young female patient with tuberculosis and renal insufficiency. Magnetic resonance (MR) has revealed the bilateral renal masses in patient, and this patient has been referred to our hospital for further management. The patient's past medical and surgical history was unremarkable.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...